Latest Licensing News

Dimerix Limited reported a 22% reduction in its FY2025 loss to $13.25 million, driven by strong licensing revenues and advancing its pivotal Phase 3 clinical trial for DMX-200. The company secured new global partnerships valued at up to AU$1.4 billion, bolstering its cash reserves and commercial prospects.

Telix Pharmaceuticals has received a Complete Response Letter from the FDA for its TLX250-CDx diagnostic agent, citing manufacturing concerns. The company plans immediate remediation and maintains its 2025 revenue guidance.

Emyria Limited reports a reduced net loss of $3.14 million for FY2025, driven by strategic expansion in psychedelic-assisted mental health treatments and key partnerships including insurer Medibank. The company advances clinical services while continuing R&D on proprietary medicines.

Tetratherix Limited reported a $9.4 million statutory loss for FY25 amid significant R&D and operational investments, successfully listing on the ASX and progressing multiple clinical and manufacturing initiatives.

Weebit Nano has reported a remarkable 300% revenue increase to $4.4 million in FY25, driven by expanding licensing deals for its advanced ReRAM technology.

Weebit Nano Limited reported a strong FY25 with revenues surging over fourfold to $4.4 million and a narrowed net loss of $38.4 million, driven by key licensing deals and progress towards automotive-grade ReRAM qualification.

Perseus Mining has reported record FY25 financial results with a 16% rise in profit after tax and announced a 50% increase in dividends alongside a renewed A$100 million share buyback program.

Alcidion Group Limited has reported a transformative FY25 with record earnings, a major NHS contract win, and a robust outlook for FY26. The company’s healthcare technology platform is gaining traction across the UK and Australia, setting the stage for accelerated growth.

Biotron Limited reported a significantly reduced net loss of $318,572 for FY2025, bolstered by a $1.27 million capital raise and a $1.81 million R&D tax rebate, as it advances clinical and preclinical antiviral programs.

BPH Energy Limited reported a 49% increase in net profit for FY2025, driven by gains in its energy and biotech investments, while facing a pivotal Federal Court hearing over the renewal of the PEP-11 offshore gas exploration permit.

Nutritional Growth Solutions has settled to exit non-core US agreements, unlocking nearly $580,000 in financial relief and streamlining its strategic focus.

archTIS Limited has reported FY25 results with solid ARR growth and completed a transformative acquisition of Spirion LLC, significantly boosting its US market presence and product suite. The company is raising $20.5 million to fund this expansion and accelerate growth.